Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

David James Pinato, MD, MRCP, PhD
Published: Friday, Apr 21, 2017



David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).

Recent biomarker studies have shown that PD-1/PD-L1 targeted therapies are an efficacious systemic treatment for patients with HCC, says Pinato. PD-1 is already used as a biomarker in clinical trials, but trials in solid tumors suggest heterogeneity in PD-L1 expression in the primary metastatic population as well.

Based on this, a study was conducted to analyze PD-L1 and PD-L2 expression by immunohistochemistry. Pinato says the findings of this study may have implications for how patients are selected for immunotherapy, but that needs further research.
 

<<< View more from the 2017 International Liver Congress



David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).

Recent biomarker studies have shown that PD-1/PD-L1 targeted therapies are an efficacious systemic treatment for patients with HCC, says Pinato. PD-1 is already used as a biomarker in clinical trials, but trials in solid tumors suggest heterogeneity in PD-L1 expression in the primary metastatic population as well.

Based on this, a study was conducted to analyze PD-L1 and PD-L2 expression by immunohistochemistry. Pinato says the findings of this study may have implications for how patients are selected for immunotherapy, but that needs further research.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x